The Procter Gamble Company

Todd Andrew Brugel

Michael Philip Clark

Adam Golebiowski

Mark Sabat

Biswanath De

Matthew John Laufersweiler

Jennifer Anne Townes

John Charles Van Rens

Roger Gunnard Bookland

Jane Far-Jine Djung

Gregory Kent Bosch

Steven Karl Laughlin

Stephen Matthew Berberich

The present invention relates to 6,7-dihydro-5H-pyrazolo[1,2&#x3b1;]pyrazol-1-ones which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions comprising said 6,7-dihydro-5H-pyrazolo[1,2&#x3b1;]pyrazol-1-ones and methods for preventing, abating, or otherwise controlling enzymes which are understood to be the active components responsible for the herein described disease states.

Bicyclic pyrazolone cytokine inhibitors

The present invention relates to 1,1,3-tri-substituted ureas which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions comprising said 1,1,3-tri-substituted ureas which inhibit the extracellular release of inflammatory cytokines, and methods for preventing, abating, or otherwise controlling enzymes which are understood to be the active components responsible for the herein described disease states.

Tri-substituted ureas as cytokine inhibitors

The present invention relates to 2,6,7-substituted pyrrolo[2,3-d]pyrimidines which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions comprising said 2,6,7-substituted pyrrolo[2,3-d]pyrimidines and methods for preventing, abating, or otherwise controlling enzymes which are understood to be the active components responsible for the herein described disease states.

Pyrrolo[2,3-d]pyrimidine cytokine inhibitors

The present invention relates to 2,8,9-substituted purines which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions comprising said 2,8,9-substituted purines and methods for preventing, abating, or otherwise controlling enzymes which are understood to be the active components responsible for the herein described disease states.

Purine cytokine inhibitors

The present invention relates to compounds which are capable of preventing the extracellular release of inflammatory cytokines, said compounds, including all enantiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, have the formula:wherein Ris substituted aryl; Ris substituted or unsubstituted aryl or heteroaryl.

6,7-dihydro-5H-pyrazolo[1,2-a]pyrazol-1-ones which control inflammatory cytokines

Spirocyclic-6,7-dihydro-5H-pyrazolo&lsqb;1,2-a&rsqb;pyrazol-1-ones which control inflammatory cytokines

Growing community of inventors

West Chester, OH, United States of America

Todd Andrew Brugel